Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment

Phase 4

Completed

• Conditions: Hypogonadism
• Interventions: Drug: Testosterone

• Registration Number: NCT02111434
• Lead Sponsor: Gulhane School of Medicine

Brief Summary

The study is designed to answer the following questions:

1. What is the levels of visceral adiposity index and Triglycerides/HDL cholesterol ratio in hypogonadism?

2. What is the effect of testosterone replacement on the visceral adiposity index and Triglycerides/HDL cholesterol ratio?

Detailed Description

This is a retrospective design, which is performed by investigating the registrations of patients with hypogonadotrophic hypogonadism between the years 2007-2010.

Study Timeline

• Study Start: 2013-07
• Status Verified: 2014-04
• Primary Completion: 2014-04
• Study Completion: 2014-04
• Study First Submitted: 2014-04-05
• Study First Submitted QC: 2014-04-09
• Last Update Submitted: 2014-04-10
• Study First Posted: 2014-04-11
• Last Update Posted: 2014-04-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 150

Inclusion Criteria

• Men
• Congenital hypogonadism
• Treatment Naive

Exclusion Criteria

• Previous history of androgen replacement
• Hypertension
• Diabetes mellitus

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
testosterone	Testosterone	testosterone gel per day for 6 months testosterone 250 mg injection per 3-4 weeks for 6 months

Primary Outcome Measures

Name	Time	Method
time to change of visceral adiposity index with testosteron replacement	baseline and 6 months
time to change of TG/HDL cholesterol ratio with testosteron replacement	baseline and 6 months

Trial Locations

Locations (1)

Gulhane School of Medicine; 🇹🇷 Ankara, Turkey